One of the best known and well-covered ETF over the past 5 years has been ARK Invest, led by Cathy Wood. With funds dropping over the past year and reaching new lows, Benzinga wondered which fund would be preferable to buy and hold.
What happened: Benzinga routinely conducts surveys Twitter Inc (NYSE: TWTR) Followers This week was used to ask a question about ark . boxes.
“If you had to choose one of the following to buy it and keep it for five years, what would it be?” Benzinga Requested.
Here’s a look at the four options, which all hit 52-week lows at some point on Friday. Prices below start from Friday afternoon when the market is closed.
ARK . innovation (NYSE: ARKK)
52-week range: $77.54 – $159.70
Top collectibles: Tesla Corporation (NASDAQ: TSLA), Zoom Video Communications Inc (NASDAQ: ZM), Teladoc Health Inc (NYSE: TDOC), company of the year (NASDAQ: ROKU) and Coinbase Global Inc (NASDAQ: currency).
One year return: -43.1%
3-year return: +97.5%
5-Year Return: +278.9%
ARK Next Generation Internet ETF (NYSE: ARKW)
52-week range: $100 – $191.13
Top collectibles: Coinbase, Tesla, Grayscale Bitcoin Box (OTC: GBTC), Zoom Video and Spotify Technology SA (NYSE: SPOT).
One year return: -33.6%
3-year return: + 128.6%
5-Year Return: +345.5%
ARK Fintech Innovation (NYSE: ARKF)
52-week range: $34.16 – $64.49
Top collectibles: block you (NYSE: SQ), Coinbase, Shopify Inc (NYSE: Store), Twilio Company (NYSE: TWLO) and UiPath Company (NYSE: PATH).
One year return: -32.2%
3-year yield: NA, launched in 2019, +41.3% since inception
5-Year Return: N/A
ARK Genomic Revolution ETF (BAT: ARKG)
52-week range: $49.70 to $115.15
Top collectibles: Institute of Exact Sciences (NASDAQ: EXAS), Teladoc, Eunice Pharmaceutical Co (NASDAQ: IONS), Fate cure (NASDAQ: FATE) and Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX).
One year return: -51.4%
3-year return: +95.8%
5-Year Return: +203.6%
Related link: Ark Innovation ETF hits 52-week low: Here are the top 5 holdings in Cathie Wood’s Flagship Fund
consequences: Benzinga users chose an overwhelming favorite in the survey with the following results recorded:
- Ark: 50.3%
- ARKG: 21.3%
- ARCF: 17.3%
- ARKW: 11.2%
The results are not too surprising given that ARK Innovation (ARKK) is the leading and most well-known fund that has enjoyed a solid five-year return.
ARK Genomic (ARKG) and ARK Fintech (ARKF) ranked second and third, respectively. Ark Genomic remains one of the only ETFs targeting the growing segment of the medical sector. The fund also has a strong three- and five-year return performance.
ARK Fintech is the ETF among the four lowest decliners of last year and also the most recent of the four. With less than three years in the market, the ETF does not have the same track record as others to track. The fund is up 41.3% since its launch and could be a good bet for the growth of fintech companies by replacing traditional banking sectors, adding cryptocurrencies and other features to propel users into the future.
ARK Next Generation Internet (ARKW) received the lowest number of votes, which comes because the box has been the best performer of the past four years. Investors may see the fund decline further in the future after a stellar five-year performance.
Photo by Christopher Roller on Unsplash